Could Caliway’s CBL-514 become a metabolic add-on to semaglutide and tirzepatide?
GLP-1 drugs drive weight loss, but rebound and body composition gaps remain. Caliway’s CBL-514 may test the next obesity frontier.
Why Pendulum Therapeutics is taking its microbiome platform beyond metabolic health with Mayo Clinic
Pendulum Therapeutics has expanded its Mayo Clinic collaboration into women’s health and dermatology. Read what this could mean for microbiome medicine.
Why Brightseed’s glycemic control data could reshape how GLP-1 companion products are evaluated
Peer-reviewed data puts Brightseed’s BioMetaControl under the clinical microscope. Find out what this trial means for GLP-1 companions and metabolic care.
Brello Rise enters the obesity care landscape as a digital wellness adjunct to medical weight loss
Brello Health launches Brello Rise, a digital studio for patients in medical weight loss programs. Find out what this signals for obesity care models.